For Cleveland BioLabs Inc., of Buffalo, N.Y., the question of the day was phrased by its vice president of pharmaceutical development, Ed Venkat, who asked, "Why did BARDA reject our white paper proposals?" Read More
Clovis Oncology Inc. wasted little time padding its coffers after an initial public offering (IPO) in November 2011 put the small biopharma in a category of one: Clovis was the only biotech to price a 2011 IPO within its initial range. Read More
Are you looking for a venture capitalist to lead your next financing round, take a seat on your board and add hands-on value to your biotech? Then Correlation Ventures is not for you. But if you've got enough of those types of investors already – maybe more than you'd like – and you just want a little money to fill out your round, give Correlation a call. Read More
• Cytos Biotechnology Ltd., of Zurich, Switzerland, said the Swiss Takeover Board approved an exemption allowing the investors in its CHF37 million (US$40.6 million) recapitalization to hold more than one-third of the company's outstanding shares when the financing closes. Read More
• Enanta Pharmaceuticals Inc., of Watertown, Mass., reported Phase II data showing that different doses of ABT-450/r, its lead candidate in its hepatitis C virus (HCV) protease inhibitor collaboration with Abbott, of Abbott Park, Ill., plus ABT-333 and ribavirin administered for 12 weeks produced sustained virological response at 12 weeks post-treatment (SVR12) in 93 percent and 95 percent of treatment-naïve genotype 1 patients. Read More
• Codexis Inc., of Redwood City, Calif., is using its CodeEvolver directed evolution technology in a collaboration with Merck & Co. Inc., of Whitehouse Station, N.J., to develop a highly efficient, cost-effective, enzyme-based production method for an intermediate used in boceprevir, the active ingredient in Merck's hepatitis C drug Victrelis. Read More
